Skip to main content
. 2022 Apr 4;12:844642. doi: 10.3389/fonc.2022.844642

Figure 2.

Figure 2

Developments and validations of prognosis model. (A, E, I) Risk value (up) and survival status (down) for each patients in the training group (A), validation group (E), and entire group (I). (B, F, J) Expression of these seven candidate biomarkers in the training group (B), validation group (F), and entire group (J). (C, G, K) Overall survival curve of patients with breast infiltrating duct and lobular carcinoma with different risk value in the training group (C), validation group (G), and entire group (J). (D, H, L) ROC curve of risk assessment model in the training group (D), validation group (H), and entire group (L). *p < 0.05, ***p < 0.001. ns, no significance.